Previous Article | Next Article 
Journal of Virology, January 2007, p. 406-410, Vol. 81, No. 1
0022-538X/07/$08.00+0 doi:10.1128/JVI.01636-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.
Control of Simian Immunodeficiency Virus SIVmac239 Is Not Predicted by Inheritance of Mamu-B*17-Containing Haplotypes
Jason A. Wojcechowskyj,1
Levi J. Yant,1,2
Roger W. Wiseman,1
Shelby L. O'Connor,2 and
David H. O'Connor1,2*
Wisconsin National Primate Research Center, University of WisconsinMadison, Madison, Wisconsin 53715,1
Department of Pathology and Laboratory Medicine, University of WisconsinMadison, Madison, Wisconsin 537152
Received 31 July 2006/
Accepted 28 September 2006

ABSTRACT
It is well established that host genetics, especially major
histocompatibility complex (MHC) genes, are important determinants
of human immunodeficiency virus disease progression. Studies
with simian immunodeficiency virus (SIV)-infected Indian rhesus
macaques have associated
Mamu-B*
17 with control of virus replication.
Using microsatellite haplotyping of the 5-Mb MHC region, we
compared disease progression among SIVmac239-infected Indian
rhesus macaques that possess
Mamu-B*
17-containing MHC haplotypes
that are identical by descent. We discovered that SIV-infected
animals possessing identical
Mamu-B*
17-containing haplotypes
had widely divergent disease courses. Our results demonstrate
that the inheritance of a particular
Mamu-B*
17-containing haplotype
is not sufficient to predict SIV disease outcome.

TEXT
Host genetics are a dominant force in determining AIDS disease
progression, viral evolution, and viral burden. Numerous studies
with human immunodeficiency virus (HIV) and simian immunodeficiency
virus (SIV), the macaque model for HIV, report strong associations
with major histocompatibility complex (MHC) genes and disease
progression (
4,
28). The human MHC alleles
HLA-B*
27 and
HLA-B*
57 and the Indian rhesus macaque alleles
Mamu-B*
17 and
Mamu-A*
01 have been linked to decreased plasma virus concentrations and
thus slowed disease progression (
12,
21,
26,
31). While the
precise mechanism of protection is unclear, mounting evidence
from CD8 depletion (
17,
27), viral transmission (
11), and viral
escape (
8,
23) studies implicates cytotoxic T lymphocytes (CTL)
as critical.
Studying correlations between MHC genetics and disease progression in HIV-infected humans is problematic because of undefined HIV inocula and the inherent genetic variability between unrelated individuals. MHC-defined Indian rhesus macaques provide an excellent resource for elucidating the influence of particular MHC alleles in SIV disease progression. Both the human allele HLA-B*57 and the rhesus allele Mamu-B*17 are overrepresented among long-term nonprogressors (21, 31), and both alleles present immunologically relevant HIV- or SIV-derived peptides to CD8+ T cells (15, 16, 22, 23). However, not all HLA-B*57-positive infected individuals or Mamu-B*17-positive infected rhesuses suppress viral replication (21, 31). It is currently unknown whether genes tightly linked to HLA-B*57 or Mamu-B*17 influence HIV or SIV disease progression.
The human MHC contains one of the most gene-dense regions in the genome, and it is estimated that of the purported 128 expressed genes, about 40% have immune function (19). When subjects are matched for multiple MHC class I alleles, the genetic backgrounds of other immune response genes located within the MHC region are typically undefined. Using microsatellites, we compared disease progression in SIVmac239-infected Indian rhesus macaques that possess identical Mamu-B*17-containing haplotypes by descent. A previous study with an MHC-defined family of SIV-infected Indian rhesus macaques demonstrated that the inheritance of putative MHC haplotypes influenced disease progression (7). While that study noted trends in survivorship within one family, we sought to determine the global influence of several Mamu-B*17-containing haplotypes on disease progression with Indian rhesus macaques infected with the clonal SIV isolate SIVmac239.
MHC haplotypes of SIV-infected Indian rhesus macaque families.
A total of 187 SIVmac239-infected Indian rhesus macaques were screened for the presence of Mamu-B*17 by sequence-specific PCR (31). Of the 44 Mamu-B*17-positive animals, 16 were chosen for analysis based on availability of archived tissue. We performed microsatellite analysis as previously described (24, 30) (Fig. 1 and data not shown). Analysis of the 16 Mamu-B*17-positive animals with respective sires and dams revealed eight distinct Mamu-B*17-containing haplotypes (Fig. 2). Five of the eight haplotypes were inherited by multiple SIV-infected animals from common sibships (Table 1). In all cases, Mamu-B*17 was inherited on a single chromosome, and no recombination events occurred between any of the microsatellites spanning the MHC (data not shown). Moreover, polymorphism within a highly informative microsatellite locus outside the MHC confirmed that none of the animals are genetically identical (data not shown).
Since chronic-phase plasma virus concentration is the best predictor
of disease progression (
18), we defined disease progression
based on the geometric mean of all measurements of plasma virus
concentration from week 10 onward. We designated animals whose
chronic geometric mean plasma virus concentration was under
10
3 viral RNA copies/ml as "elite controllers." Although this
retrospective study used animals that were administered various
vaccines, there was no correlation of vaccination with elite
control (
31). When the entire 5-Mb MHC region was considered,
none of the eight
Mamu-B*
17-containing haplotypes unambiguously
correlated with elite control (Fig.
2). Additionally, none of
the eight
Mamu-B*
17-containing haplotypes were identical to
one another. This supports a previous observation that Indian
rhesus MHC microsatellite haplotypes are identical only in related
animals (
24), underscoring the MHC diversity inherent even when
animals share one or more MHC class I alleles.
To more closely examine the class IB region microsatellite haplotypes among Mamu-B*17-positive animals, we identified additional polymorphic microsatellites in the class IB region (Fig. 1). Shared between all Mamu-B*17 haplotypes was a region defined by microsatellites L13-1494 and G09-164763 (Fig. 1 and 2). One microsatellite in this region, H11-9268, showed exceptional linkage to Mamu-B*17. As supported by a microsatellite analysis of 75 Indian rhesus macaques, the microsatellite allele value of 235 for H11-9268 was found only in Mamu-B*17-positive animals (n = 25) and not in Mamu-B*17-negative animals (n = 50) (data not shown). This suggests a putative location for Mamu-B*17 near the Mamu-B4 gene defined by Daza-Vamenta et al. (6) and provides a robust and simple technology for genotyping Indian rhesus macaques for Mamu-B*17. Additionally, this technology can greatly improve breeding for Mamu-B*17-positive macaques by identifying sires and dams homozygous for Mamu-B*17.
Elite control is not predicted by inherited MHC haplotype.
We observed dramatic variation of chronic-phase viral loads in animals possessing identical Mamu-B*17 haplotypes (Table 1). In those haplotypes inherited by at least one SIV controller (haplotypes A through D), the same Mamu-B*17 haplotype was associated with control in some but not all animals, with the exception of haplotype D, where only one animal was available (Table 1). For example, geometric mean plasma virus concentrations from animals possessing haplotype A ranged from 361 to 1,430,000 viral RNA copies/ml (Table 1). When plasma virus concentrations from haplotype A are plotted versus time, dramatic variation is evident (Fig. 3). In animals possessing haplotypes A through C and E, we observed a variation of chronic-phase plasma virus concentrations of at least 2 log units (Table 1 and Fig. 3). None of the five Mamu-B*17-containing haplotypes found in more than one animal were unambiguously associated with SIV control, even though animals were infected with identical virus. Therefore, we conclude that the inheritance of a particular Mamu-B*17-containing 5-Mb MHC haplotype alone is not sufficient to predict SIV disease outcome.
Since entire 5-Mb MHC haplotypes were controlled for, any effect
from genes linked to
Mamu-B*
17 or sequence variants in
Mamu-B*
17 regulatory elements should be apparent. Our results show that
these factors do not explain variation in SIV disease progression
in
Mamu-B*
17-positive animals. Although MHC class I allele differences
between animals can influence the CTL repertoire (
5,
29), we
were able to completely match animals for half of their MHC
genes.
We cannot, however, exclude the possibility that genes on the other MHC haplotype modulate the effect of Mamu-B*17. Ideally, this could be examined by studying full siblings who inherit the Mamu-B*17-containing haplotype from one parent and an identical haplotype from their other parent. Using our panel of microsatellite markers, we discovered one full sibling pair that met these criteria. Animal 97035 is completely MHC identical to animal 95096 by descent (data not shown). Animal 97035 was infected with an SIVmac239 variant mutated in the Mamu-B*17-restricted Nef IW9 epitope and was thus excluded from this study (10). Nonetheless, both 95096 and 97035 controlled SIV for more than 3 years. Expanded studies of MHC-identical full siblings will be required to determine the extent to which sharing of both haplotypes predicts SIV control.
An unresolved question is whether differences in Mamu-B*17-restricted T-cell responses or immune escape from these responses account for the differences in viral load among animals inheriting the same Mamu-B*17 haplotype. In HIV-infected people, the breadth and magnitude of CTL responses restricted by HLA-B*5701 are not markedly different between controllers and progressors, even though HLA-B*5701, like Mamu-B*17, is highly overrepresented among HIV controllers (20). We examined CTL activity against the immunodominant, Mamu-B*17-restricted Nef165-173IW9 epitope (22) by gamma interferon enzyme-linked immunospot in all but four of the animals shown in Table 1. All animals except 97044 mounted Nef IW9 responses, but there was no consistent difference in response magnitude between the progressors and controllers. More subtle quantitative differences in CTL activity might be revealed by studying additional subdominant Mamu-B*17-restricted epitopes (9) and by testing cells obtained at the same time point following infection. The sporadic availability of samples from animals in the current study required assessment of Nef IW9-specific CTL from between 6 and 324 weeks postinfection.
We also analyzed viral escape from Nef IW9 CTL responses in these animals. Though many groups have examined proviral SIV (23) and HIV (1, 20) sequences from individuals who control virus, the relationship between these sequences and replicating virus is questionable (2). We coupled ultrasensitive viral RNA extraction with reverse transcription-PCR using amplification primers flanking the Nef IW9 epitope sequence to extract viral sequence from plasma virus. This approach successfully generated sequence from samples containing fewer than 100 copies of virus per ml of plasma. Chronic-phase sequence variation was pervasive within the Nef IW9 epitope in both SIV controllers and progressors (Table 1). Therefore, SIV control is not likely to be attributable to the unusual preservation of wild-type Nef IW9 epitope sequences.
While plasma virus concentrations from Mamu-B*17-positive infected animals are generally lower than those from Mamu-B*17-negative animals (31), we speculate that loci outside the MHC may explain the stark difference in SIV disease progression among animals possessing the same Mamu-B*17 haplotype. Surveying the genome for additional loci involved in SIV and HIV control is thus an urgent priority. Though resources such as rhesus macaque linkage maps (25) will further the search for other quantitative trait loci associated with SIV resistance, the haplotype diversity among Mamu-B*17-positive controllers suggests that such analyses will not be simple or straightforward. Indeed, comprehensive identification of genes involved in SIV control using functional genomics would likely require hundreds of animals with defined SIV pathogenesis and unprecedented cooperation among the many investigators possessing samples from these animals. Inspiration for this ambitious undertaking can be drawn from other large-scale collaborative efforts recently initiated to answer fundamental questions about HIV and SIV pathogenesis (3, 13, 14).
In all, our results suggest that inheritance of haplotypes containing "protective" MHC class I alleles alone does not predict SIV disease outcome and thus is unlikely the sole factor conferring protection during SIV infection.

ACKNOWLEDGMENTS
This publication was made possible in part by grant number P51
RR000167 from the National Center for Research Resources (NCRR),
a component of the National Institutes of Health (NIH), to the
Wisconsin National Primate Research Center, University of WisconsinMadison.
This research was conducted in part at a facility constructed
with support from Research Facilities Improvement Program grant
numbers RR15459-01 and RR020141-01.
This publication's contents are solely the responsibility of the authors and do not necessarily represent the official views of NCRR or NIH.

FOOTNOTES
* Corresponding author. Mailing address: University of WisconsinMadison, 555 Science Dr., Madison, WI 53711. Phone: (608) 890-0845. Fax: (608) 265-8084. E-mail:
doconnor{at}primate.wisc.edu.

Published ahead of print on 1 November 2006. 

REFERENCES
1 - Allen, T. M., M. Altfeld, S. C. Geer, et al. 2005. Selective escape from CD8+ T-cell responses represents a major driving force of human immunodeficiency virus type 1 (HIV-1) sequence diversity and reveals constraints on HIV-1 evolution. J. Virol. 79:13239-13249.[Abstract/Free Full Text]
2 - Bailey, J. R., A. R. Sedaghat, T. Kieffer, et al. 2006. Residual human immunodeficiency virus type 1 viremia in some patients on antiretroviral therapy is dominated by a small number of invariant clones rarely found in circulating CD4+ T cells. J. Virol. 80:6441-6457.[Abstract/Free Full Text]
3 - Basu, P. 2006. Ambitious AIDS grants deepen rift between researchers. Nat. Med. 12:865.[CrossRef][Medline]
4 - Bontrop, R. E., and D. I. Watkins. 2005. MHC polymorphism: AIDS susceptibility in non-human primates. Trends Immunol. 26:227-233.[CrossRef][Medline]
5 - Boon, A. C., G. De Mutsert, R. A. Fouchier, et al. 2004. Preferential HLA usage in the influenza virus-specific CTL response. J. Immunol. 172:4435-4443.[Abstract/Free Full Text]
6 - Daza-Vamenta, R., G. Glusman, L. Rowen, B. Guthrie, and D. E. Geraghty. 2004. Genetic divergence of the rhesus macaque major histocompatibility complex. Genome Res. 14:1501-1515.[Abstract/Free Full Text]
7 - Evans, D. T., P. Jing, T. M. Allen, et al. 2000. Definition of five new simian immunodeficiency virus cytotoxic T-lymphocyte epitopes and their restricting major histocompatibility complex class I molecules: evidence for an influence on disease progression. J. Virol. 74:7400-7410.[Abstract/Free Full Text]
8 - Feeney, M. E., Y. Tang, K. A. Roosevelt, et al. 2004. Immune escape precedes breakthrough human immunodeficiency virus type 1 viremia and broadening of the cytotoxic T-lymphocyte response in an HLA-B27-positive long-term-nonprogressing child. J. Virol. 78:8927-8930.[Abstract/Free Full Text]
9 - Frahm, N., P. Kiepiela, S. Adams, et al. 2006. Control of human immunodeficiency virus replication by cytotoxic T lymphocytes targeting subdominant epitopes. Nat. Immunol. 7:173-178.[CrossRef][Medline]
10 - Friedrich, T. C., E. J. Dodds, L. J. Yant, et al. 2004. Reversion of CTL escape-variant immunodeficiency viruses in vivo. Nat. Med. 10:275-281.[CrossRef][Medline]
11 - Goulder, P. J., C. Brander, Y. Tang, et al. 2001. Evolution and transmission of stable CTL escape mutations in HIV infection. Nature 412:334-338.[CrossRef][Medline]
12 - Kiepiela, P., A. J. Leslie, I. Honeyborne, et al. 2004. Dominant influence of HLA-B in mediating the potential co-evolution of HIV and HLA. Nature 432:769-775.[CrossRef][Medline]
13 - Klausner, R. D., A. S. Fauci, L. Corey, et al. 2003. Medicine. The need for a global HIV vaccine enterprise. Science 300:2036-2039.[Abstract/Free Full Text]
14 - Koff, W. C., P. R. Johnson, D. I. Watkins, et al. 2006. HIV vaccine design: insights from live attenuated SIV vaccines. Nat. Immunol. 7:19-23.[CrossRef][Medline]
15 - Leslie, A. J., K. J. Pfafferott, P. Chetty, et al. 2004. HIV evolution: CTL escape mutation and reversion after transmission. Nat. Med. 10:282-289.[CrossRef][Medline]
16 - Martinez-Picado, J., J. G. Prado, E. E. Fry, et al. 2006. Fitness cost of escape mutations in p24 Gag in association with control of human immunodeficiency virus type 1. J. Virol. 80:3617-3623.[Abstract/Free Full Text]
17 - Matano, T., R. Shibata, C. Siemon, et al. 1998. Administration of an anti-CD8 monoclonal antibody interferes with the clearance of chimeric simian/human immunodeficiency virus during primary infections of rhesus macaques. J. Virol. 72:164-169.[Abstract/Free Full Text]
18 - Mellors, J. W., C. R. Rinaldo, Jr., P. Gupta, et al. 1996. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 272:1167-1170.[Abstract]
19 - The MHC Sequencing Consortium. 1999. Complete sequence and gene map of a human major histocompatibility complex. Nature 401:921-923.[CrossRef][Medline]
20 - Migueles, S. A., A. C. Laborico, H. Imamichi, et al. 2003. The differential ability of HLA B*5701+ long-term nonprogressors and progressors to restrict human immunodeficiency virus replication is not caused by loss of recognition of autologous viral gag sequences. J. Virol. 77:6889-6898.[Abstract/Free Full Text]
21 - Migueles, S. A., M. S. Sabbaghian, W. L. Shupert, et al. 2000. HLA B*5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressors. Proc. Natl. Acad. Sci. USA 97:2709-2714.[Abstract/Free Full Text]
22 - Mothe, B. R., J. Sidney, J. L. Dzuris, et al. 2002. Characterization of the peptide-binding specificity of Mamu-B*17 and identification of Mamu-B*17-restricted epitopes derived from simian immunodeficiency virus proteins. J. Immunol. 169:210-219.[Abstract/Free Full Text]
23 - O'Connor, D. H., B. R. Mothe, J. T. Weinfurter, et al. 2003. Major histocompatibility complex class I alleles associated with slow simian immunodeficiency virus disease progression bind epitopes recognized by dominant acute-phase cytotoxic-T-lymphocyte responses. J. Virol. 77:9029-9040.[Abstract/Free Full Text]
24 - Penedo, M. C., R. E. Bontrop, C. M. Heijmans, et al. 2005. Microsatellite typing of the rhesus macaque MHC region. Immunogenetics 57:198-209.[CrossRef][Medline]
25 - Rogers, J., R. Garcia, W. Shelledy, et al. 2006. An initial genetic linkage map of the rhesus macaque (Macaca mulatta) genome using human microsatellite loci. Genomics 87:30-38.[CrossRef][Medline]
26 - Saah, A. J., D. R. Hoover, S. Weng, et al. 1998. Association of HLA profiles with early plasma viral load, CD4+ cell count and rate of progression to AIDS following acute HIV-1 infection. AIDS 12:2107-2113.[CrossRef][Medline]
27 - Schmitz, J. E., M. J. Kuroda, S. Santra, et al. 1999. Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science 283:857-860.[Abstract/Free Full Text]
28 - Stephens, H. A. 2005. HIV-1 diversity versus HLA class I polymorphism. Trends Immunol. 26:41-47.[CrossRef][Medline]
29 - Tourdot, S., and K. G. Gould. 2002. Competition between MHC class I alleles for cell surface expression alters CTL responses to influenza A virus. J. Immunol. 169:5615-5621.[Abstract/Free Full Text]
30 - Wiseman, R. W., J. A. Wojcechowskyj, J. M. Greene, A. J. Blasky, T. Gopon, T. Soma, T. C. Friedrich, S. L. O'Connor, and D. H. O'Connor. 2007. Simian immunodeficiency virus SIVmac239 infection of major histocompatibility complex-identical cynomolgus macaques from Mauritius. J. Virol. 81:349-361.[Abstract/Free Full Text]
31 - Yant, L. J., T. C. Friedrich, R. C. Johnson, et al. 2006. The high-frequency major histocompatibility complex class I allele Mamu-B*17 is associated with control of simian immunodeficiency virus SIVmac239 replication. J. Virol. 80:5074-5077.[Abstract/Free Full Text]
Journal of Virology, January 2007, p. 406-410, Vol. 81, No. 1
0022-538X/07/$08.00+0 doi:10.1128/JVI.01636-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.
This article has been cited by other articles:
-
Elbim, C., Monceaux, V., Mueller, Y. M., Lewis, M. G., Francois, S., Diop, O., Akarid, K., Hurtrel, B., Gougerot-Pocidalo, M.-A., Levy, Y., Katsikis, P. D., Estaquier, J.
(2008). Early Divergence in Neutrophil Apoptosis between Pathogenic and Nonpathogenic Simian Immunodeficiency Virus Infections of Nonhuman Primates. J. Immunol.
181: 8613-8623
[Abstract]
[Full Text]
-
Bimber, B. N., Moreland, A. J., Wiseman, R. W., Hughes, A. L., O'Connor, D. H.
(2008). Complete Characterization of Killer Ig-Like Receptor (KIR) Haplotypes in Mauritian Cynomolgus Macaques: Novel Insights into Nonhuman Primate KIR Gene Content and Organization. J. Immunol.
181: 6301-6308
[Abstract]
[Full Text]
-
Maness, N. J., Yant, L. J., Chung, C., Loffredo, J. T., Friedrich, T. C., Piaskowski, S. M., Furlott, J., May, G. E., Soma, T., Leon, E. J., Wilson, N. A., Piontkivska, H., Hughes, A. L., Sidney, J., Sette, A., Watkins, D. I.
(2008). Comprehensive Immunological Evaluation Reveals Surprisingly Few Differences between Elite Controller and Progressor Mamu-B*17-Positive Simian Immunodeficiency Virus-Infected Rhesus Macaques. J. Virol.
82: 5245-5254
[Abstract]
[Full Text]
-
Loffredo, J. T., Bean, A. T., Beal, D. R., Leon, E. J., May, G. E., Piaskowski, S. M., Furlott, J. R., Reed, J., Musani, S. K., Rakasz, E. G., Friedrich, T. C., Wilson, N. A., Allison, D. B., Watkins, D. I.
(2008). Patterns of CD8+ Immunodominance May Influence the Ability of Mamu-B*08-Positive Macaques To Naturally Control Simian Immunodeficiency Virus SIVmac239 Replication. J. Virol.
82: 1723-1738
[Abstract]
[Full Text]
-
Giraldo-Vela, J. P., Rudersdorf, R., Chung, C., Qi, Y., Wallace, L. T., Bimber, B., Borchardt, G. J., Fisk, D. L., Glidden, C. E., Loffredo, J. T., Piaskowski, S. M., Furlott, J. R., Morales-Martinez, J. P., Wilson, N. A., Rehrauer, W. M., Lifson, J. D., Carrington, M., Watkins, D. I.
(2008). The Major Histocompatibility Complex Class II Alleles Mamu-DRB1*1003 and -DRB1*0306 Are Enriched in a Cohort of Simian Immunodeficiency Virus-Infected Rhesus Macaque Elite Controllers. J. Virol.
82: 859-870
[Abstract]
[Full Text]
-
Loffredo, J. T., Maxwell, J., Qi, Y., Glidden, C. E., Borchardt, G. J., Soma, T., Bean, A. T., Beal, D. R., Wilson, N. A., Rehrauer, W. M., Lifson, J. D., Carrington, M., Watkins, D. I.
(2007). Mamu-B*08-Positive Macaques Control Simian Immunodeficiency Virus Replication. J. Virol.
81: 8827-8832
[Abstract]
[Full Text]
-
Wiseman, R. W., Wojcechowskyj, J. A., Greene, J. M., Blasky, A. J., Gopon, T., Soma, T., Friedrich, T. C., O'Connor, S. L., O'Connor, D. H.
(2007). Simian Immunodeficiency Virus SIVmac239 Infection of Major Histocompatibility Complex-Identical Cynomolgus Macaques from Mauritius. J. Virol.
81: 349-361
[Abstract]
[Full Text]